These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32557325)

  • 1. Effect of angiotensin II blockers on the prognosis of COVID-19: a toxicological view.
    Shirazi FM; Banerji S; Nakhaee S; Mehrpour O
    Eur J Clin Microbiol Infect Dis; 2020 Oct; 39(10):2001-2002. PubMed ID: 32557325
    [No Abstract]   [Full Text] [Related]  

  • 2. Outcomes of renin-angiotensin-aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis.
    Greco A; Buccheri S; D'Arrigo P; Calderone D; Agnello F; Monte M; Milluzzo RP; Franchina AG; Ingala S; Capodanno D
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):335-337. PubMed ID: 32671399
    [No Abstract]   [Full Text] [Related]  

  • 3. Covid-19: Time for a paradigm change.
    Buonaguro FM; Ascierto PA; Morse GD; Buonaguro L; Puzanov I; Tornesello ML; Bréchot C; Gallo RC
    Rev Med Virol; 2020 Sep; 30(5):e2134. PubMed ID: 32618072
    [No Abstract]   [Full Text] [Related]  

  • 4. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin.
    Theoharides TC
    Biofactors; 2020 May; 46(3):306-308. PubMed ID: 32339387
    [No Abstract]   [Full Text] [Related]  

  • 5. Using "old" medications to fight new COVID-19: Re-purposing with a purpose.
    Wang Y; Foo R; Thum T
    J Mol Cell Cardiol; 2020 Sep; 146():41-42. PubMed ID: 32687852
    [No Abstract]   [Full Text] [Related]  

  • 6. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.
    Seif F; Aazami H; Khoshmirsafa M; Kamali M; Mohsenzadegan M; Pornour M; Mansouri D
    Int Arch Allergy Immunol; 2020; 181(6):467-475. PubMed ID: 32392562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 and relative angiotensin-converting enzyme 2 deficiency: role in disease severity and therapeutic response.
    Ryan PM; Caplice N
    Open Heart; 2020 Jun; 7(1):. PubMed ID: 32532804
    [No Abstract]   [Full Text] [Related]  

  • 8. Pre- and post-treatment chest CT changes in a patient with COVID-19.
    Fu B; Qian K; Fu X
    Med Clin (Barc); 2020 Jul; 155(1):49. PubMed ID: 32417029
    [No Abstract]   [Full Text] [Related]  

  • 9. Repurposing of host-based therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19): a link between antiviral and anticancer mechanisms?
    Alonso DF; Farina HG
    Int J Antimicrob Agents; 2020 Sep; 56(3):106125. PubMed ID: 32739476
    [No Abstract]   [Full Text] [Related]  

  • 10. Modeling Potential Autophagy Pathways in COVID-19 and Sarcoidosis.
    Calender A; Israel-Biet D; Valeyre D; Pacheco Y
    Trends Immunol; 2020 Oct; 41(10):856-859. PubMed ID: 32863134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers.
    Bavishi C; Maddox TM; Messerli FH
    JAMA Cardiol; 2020 Jul; 5(7):745-747. PubMed ID: 32242890
    [No Abstract]   [Full Text] [Related]  

  • 12. The Potential Benefit of Telmisartan to Protect Overweight Patients with COPD from the Acquisition of COVID-19.
    Kow CS; Hasan SS
    Obesity (Silver Spring); 2020 Nov; 28(11):2035. PubMed ID: 32692903
    [No Abstract]   [Full Text] [Related]  

  • 13. After 62 years of regulating immunity, dexamethasone meets COVID-19.
    Cain DW; Cidlowski JA
    Nat Rev Immunol; 2020 Oct; 20(10):587-588. PubMed ID: 32778829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of ACE2 receptor and ACEIs/ARBs with disease severity in COVID-19.
    Sinha S; Sehgal A; Sehgal R
    Drug Discov Ther; 2020; 14(4):161-170. PubMed ID: 32908071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAAS blockers in hypertension posing a higher risk toward the COVID-19.
    Singh Y; Gupta G; Satija S; Negi P; Chellappan DK; Dua K
    Dermatol Ther; 2020 Jul; 33(4):e13501. PubMed ID: 32359088
    [No Abstract]   [Full Text] [Related]  

  • 16. Successful use of methylprednisolone for treating severe COVID-19.
    Liu J; Zheng X; Huang Y; Shan H; Huang J
    J Allergy Clin Immunol; 2020 Aug; 146(2):325-327. PubMed ID: 32479759
    [No Abstract]   [Full Text] [Related]  

  • 17. Statin therapy and SAR-COV-2: an available and potential therapy?
    Abdel-Latif RG; Mohammed S; Elgendy IY
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):333-334. PubMed ID: 32379307
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.
    Yeleswaram S; Smith P; Burn T; Covington M; Juvekar A; Li Y; Squier P; Langmuir P
    Clin Immunol; 2020 Sep; 218():108517. PubMed ID: 32585295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV.
    Lubbe L; Cozier GE; Oosthuizen D; Acharya KR; Sturrock ED
    Clin Sci (Lond); 2020 Nov; 134(21):2851-2871. PubMed ID: 33146371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes of CT findings in a 2019 novel coronavirus (2019-nCoV) pneumonia patient.
    Fang X; Zhao M; Li S; Yang L; Wu B
    QJM; 2020 Apr; 113(4):271-272. PubMed ID: 32073631
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.